FORMAC obtains EMA Orphan Drug Designation for FP110
FORMAC Pharmaceuticals N.V. announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to FORMAC's FP110.
This Orphan Drug Designation follows a similar decision from the Food & Drug Administration (FDA). It is another important milestone for the program, following the promising results obtained during a phase 2A clinical trial with patients suffering from pouchitis. Pouchitis is a debilitating condition for which there is no approved treatment and the EMA's decision also reflects the high unmet medical need for patients suffering from this condition.
"We made excellent progress in securing the additional clinical data ", says Jan Rosier, FORMAC's Chief Executive Officer, "and we have started negotiations with identified potential partners to make this promising and important product available to patients".
Other news from the department research and development
